About the role
Mavericks Wanted
When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on
In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible.
Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work.
What You'll Do
BridgeBio is seeking an Access & Reimbursement Director – Rare Disease (Hybrid Reimbursement & Patient Support) responsible for executing the launch strategy across a rare disease portfolio including integrating provider-facing reimbursement strategy with patient access and support coordination across a rare disease portfolio.
This hybrid role operates at an Associate Director level of autonomy and cross-functional influence, serving as a regional expert in navigating complex reimbursement pathways while supporting compliant education and coordination related to patient access and support programs.
The Associate Director partners with healthcare providers, consented patients and care partners, specialty pharmacies, and internal stakeholders to support patient understanding of reimbursement, affordability, and access processes in a compliant and ethical manner.
This position reports into Market Access / Patient Services leadership and works in close collaboration with Medical, Compliance, Legal, Commercial, Sales, and Patient Services teams.
Responsibilities
Reimbursement & Access Strategy (Provider-Facing)
- Serve as a regional subject matter expert on reimbursement and access for BridgeBio therapies
- Educate healthcare provider offices on reimbursement processes, including benefits investigation, prior authorization, appeals, and coverage pathways
- Identify and compliantly address access barriers within commercial and government payer environments
- Support integration of access processes into provider office workflows
- Provide compliant education on BridgeBio patient support programs and services
- Share payer policy trends and field insights with Market Access leadership to inform strategy
Patient Support & Access Coordination
- Provide access and affordability education to consented patients and care partners in alignment with compliance and privacy regulations
- Support understanding of reimbursement processes and available patient support resources
- Coordinate, as appropriate, among hubs, specialty pharmacies, prescriber offices, and support programs to facilitate continuity of access
- Assist in identifying and escalating access-related challenges impacting the patient journey
- Support onboarding and ongoing engagement of consented patients within BridgeBio patient support programs in accordance with progr
Aplyr's read
BridgeBio Pharma is a dynamic biotechnology firm dedicated to tackling genetic diseases and cancers, attracting professionals passionate about impactful medical advancements.
What's promising
- •BridgeBio focuses on innovative treatments for genetic diseases, offering significant potential for groundbreaking medical advancements.
- •The company has a robust pipeline with multiple late-stage clinical trials, indicating strong future growth prospects.
- •BridgeBio's strategic partnerships enhance its research capabilities and expand its therapeutic reach.
What to watch
- •The company faces high financial risk due to significant R&D expenditures without guaranteed success.
- •BridgeBio operates in a highly competitive market with numerous established players.
- •Regulatory hurdles for drug approvals can delay product launches and impact revenue.
Why BridgeBio Pharma
- •BridgeBio's focus on genetic diseases and cancers sets it apart in the biotechnology sector.
- •The company's decentralized model allows for nimble and efficient project management.
- •BridgeBio's commitment to rare diseases addresses unmet medical needs, differentiating its mission.
Aplyr’s read is generated by AI from public sources. Was it useful?
About BridgeBio Pharma
BridgeBio is a biotechnology company focused on developing and commercializing medicines for genetic diseases and cancers.
